Neuropathology for the Neuroradiologist: Plaques and Tangles

F.J. Wippold II, N. Cairns, K. Vo, D.M. Holtzman and J.C. Morris

*AJNR Am J Neuroradiol* 2008, 29 (1) 18-22
doi: https://doi.org/10.3174/ajnr.A0781
http://www.ajnr.org/content/29/1/18
Neuropathology for the Neuroradiologist: Plaques and Tangles

Histologically identified cellular deposits often provide a tissue diagnosis as well as clues about the pathogenesis of the disease that they represent. Two distinctive structures seen within brains of patients with dementia of the Alzheimer type (DAT) are plaques and tangles. Appreciation of these tissue inclusions enhances the interactions of the neuroradiologist with the neuropathologist, neurologist, geriatric psychiatrist, and geriatrician and deepens the understanding of Alzheimer disease (AD), the all-too-common neurodegenerative disorder. Moreover, neuroradiologists are likely to play important roles in the future regarding the detection and differential diagnosis of AD, given the increasing prevalence of DAT in the aging population and promising research aided by such tools as positron-emission tomography (PET), quantitative structural imaging, molecular imaging, diffusion tensor imaging, and functional MR imaging. The purpose of this report is to review the significance of plaques and neurofibrillary tangles in the context of Alzheimer disease.

SUMMARY: Histologically identified intracellular and extracellular inclusions and structures often provide a tissue diagnosis of a specific disease process. Moreover, these deposits may provide clues about the pathogenesis of the disease in which they are found. Two distinctive structures seen within the brains of patients clinically diagnosed with dementia of the Alzheimer type are extracellular plaques and intracellular neurofibrillary tangles. The purpose of this report is to review the significance of plaques and neurofibrillary tangles in AD.

Background
In November 1901, a 51-year-old woman living in Frankfort, Germany, experienced increasing confusion, paranoia, and delusions and was admitted to the local asylum. There she was examined by the young psychiatrist Alois Alzheimer (1864–1915).1–3 Auguste D., as she was named in various reports, was fascinating in that her obvious dementia and complicating psychosis occurred at a much earlier age than the often-observed dementia of the elderly and that her deterioration progressed relatively rapidly.4 Following her hospitalization, Alzheimer left Frankfurt to join the famed pioneer of psychiatric diagnosis as psychiatric illness.5,6 When Auguste D. died in 1906, her brain was sent to Alzheimer in Munich for dissection at his request. He would present his findings at the 37th annual meeting of Southwest German psychiatrists in Tübingen, Germany, in November of that year, and would publish the account in 1907.7 His terse but extraordinarily prescient observations would launch a century of investigation into the causes of this early-onset dementia.

In that report, Alzheimer described miliary foci of extracellular structures, which would later be known as “plaques” as well as previously unrecognized intracellular flame-shaped fiberlike bundles that would be named “tangles.”8,9 Alzheimer was a fastidious observer and excellent microscopist, and his descriptions are still regarded as highly accurate. Alzheimer’s student and colleague, Gaetano Perusini (1879–1915), would later compile 4 cases, including Alzheimer’s original patient, and would more fully outline the clinical and pathologic findings.9,10 By 1910, Alzheimer had extensively studied the 3-year downhill course of a second patient, Johann F., a 56-year-old day laborer. Notably, this patient did not demonstrate tangles.1,11,12 Convinced that the early onset distinguished these patients, Kraepelin honored his protégé by naming the presenile dementia “Alzheimer disease” in the eighth edition of his then-standard psychiatry textbook.5,13–16 Alzheimer’s contribution to knowledge about presenile dementia resides in his identification of the clinical and pathologic features of the disorder, which, in turn, contributed to the recognition that dementia was an illness rather than an expected phenomenon of aging. Refinement of pathologic techniques some decades later would rekindle interest in this disorder.

What Are Plaques?
Alzheimer’s first foundational observation was the presence of small spheric structures within the cerebral cortex, measuring 10–160 μm in diameter, which he termed “drusen” or plaques.17,18 Alzheimer was not the first investigator to describe cerebral plaques, though he was the first individual to record their presence in the presenile form of dementia. Several earlier researchers had noted similar inclusions in the cortex of autopsied elderly patients with dementia.17,19–22 Even the acclaimed Czech neurologist and psychiatrist, Arnold Pick...
Kraepelin’s archrival and chief psychiatrist at the University of Prague, who is now known for the frontotemporal subtype of dementia that bears his name, had recognized focal abnormalities in the cortex of an elderly patient.3

Plaques are proteinaceous extracellular deposits consisting primarily of amyloid-β (Aβ) peptide fragments. The most abundant species of Aβ found in plaques are either 40 or 42 amino acid residues in length (Fig 1).18,21,23,24 The β designation is derived from the secondary structure of the constituent protein in which parallel strands of amino acids are laterally associated with each other due to hydrogen bondings to form a sheetlike configuration of protein known as a β-pleated sheet. Curiously, the name “amyloid” (derived from Latin “amylum” or starch), as coined by the famous German pathologist and statesman, Rudolph Ludwig Karl Virchow (1821–1902), is a misnomer, because he thought the protein was actually a starchlike compound, due to its behavior with periodic-acid-Schiff stain.25 In addition to the Aβ peptide, plaques also contain a variety of other components such as apolipoprotein E, α-1-antichymotrypsin, and proteoglycans.18,24

Associated with many of the plaques is evidence of inflammation and abnormal neuronal processes called dystrophic neurites.24 Fibrous astrocytes demonstrating increased amounts of glial fibrillary acidic protein (GFAP) mark this inflammatory response.18,26 GFAP is a cytoskeletal intermediate protein filament involved in glial cell adhesion, motility, and shape and tends to be upregulated in stress and injury.27-30

Fibrous astrocytes also appear in regions of neurofibrillary tangles (NFTs) and neuronal loss.18 Additionally, activated microglia surround plaques. They likely participate in pathogenesis, but their exact role remains unclear.18

The dystrophic neurites, consisting of swollen axons and dendrites containing lysosome-related attenuated bodies, immunologically stain for chromogranin A and ubiquitin. Chromogranin A is a secretory protein found in neurons and endocrine cells, and ubiquitin is a protein that regulates nonlysosomal degradation of other proteins.27,31-33 Some of these neurites may also contain paired helical filaments, which are strands of an aggregated protein known as τ, wound in a leftward configuration, repeating every 80 nm.24,34,35

Several types of plaques have been described. Diffuse plaques are focal poorly margined collections of aggregated Aβ peptide that are not fibrillar and that lack dystrophic neurites, glial reaction, or any organized internal architecture.18,36 Neuritic plaques contain an attenuated central core of fibrillar Aβ peptide and have neighboring dystrophic neurites.18,24,37 They are associated with the degeneration observed at the synaptic junction and are surrounded by reactive astrocytes and activated microglial cells.24,37 Neuritic plaques also frequently are associated complement factors and immunoglobulins and a surrounding halo that includes fiberlike structures.37,38 Finally, so-called burnt-out plaques represent an end stage process and feature a condensed amyloid core without associated neurites.24 Some investigators contend that the stages of

![Fig 1](https://www.ajnr.org)

**Fig 1.** A, Atrophy of the brain. On the left, a section of the hemibrain of a 70-year-old patient with AD and, on the right, a healthy aged control brain. The AD brain shows marked atrophy, dilation of the lateral ventricle, and a small hippocampus. B, Neurofibrillary tangles (N) and neuritic plaques (P) in the hippocampus. Modified Bielschowsky silver impregnation. C, β-amyloidosis in the frontal lobe: a diffuse plaque (D), a cored plaque (C), and cerebral amyloid angiopathy (A). β-amyloid (10D5) immunohistochemistry. D, Neurofibrillary tangles (N) and neuritic plaques (P) in the frontal lobe. Phosphorylated δ immunohistochemistry.
plaque development and resultant neuronal damage begin with the formation of the diffuse plaque, which then advances to the neuritic variety and eventually concludes with the burnt-out type.\textsuperscript{24,39} There is, however, no direct evidence that an evolution of plaque formation occurs.

Plaques occur abundantly in regions of the association areas of the neocortex, posterior cingulate, and limbic cortex.\textsuperscript{18} With the progression of the disease, plaque attenuation increases, with only late involvement of the primary sensory and motor areas.\textsuperscript{40}

**What Are Tangles?**

Although plaques had been previously recognized, Alzheimer’s novel observation was the presence of intraneuronal NFTs (“Fibrillenbundel”).\textsuperscript{7,17} These tangles resemble condensed serpentine fibrils and are primarily composed of $\tau$ protein arranged in hyperphosphorylated paired helical strands (Fig 1).\textsuperscript{23,34,41} Normal $\tau$ protein promotes the assembly of microtubules, which, in turn, help organize the 3D architecture of the neuron and assist in the transportation of protein and enzyme-containing vesicles essential in cell maintenance and function.\textsuperscript{42} For unclear reasons, $\tau$ protein aggregates inside neurons and their processes, and microtubules tend to depolymerize. This process is associated with hyperphosphorylation of $\tau$ protein and likely disrupts normal microtubule function. In addition, aggregated $\tau$ protein itself may lead to neuronal dysfunction.\textsuperscript{23,43} The cause for the abnormal phosphorylation is unclear, but altered function of several protein kinases or phosphatases or a maladaptation due to cellular or microenvironmental stress may be implicated.\textsuperscript{44,45}

Initially, the $\tau$ protein is dispersed within the neurons. As it aggregates into defined filaments, silver staining reveals the classic NFTs within the neuronal cell bodies and dendrites. With the death of the neurons, the NFTs remain as extracellular “ghost tangles” or “tombstones.”\textsuperscript{24} The NFTs demonstrate a consistent pattern of involvement that may be useful for staging the disease in autopsied brain specimens.\textsuperscript{18,40,46,47} Patients with preclinical DAT have significant entorhinal cortex involvement with progression to the limbic cortex and eventually the isocortex as the disease clinically advances.\textsuperscript{10,46,47} However, $\tau$ pathology is not restricted to DAT. NFTs have also been identified in neurons, astrocytes, and oligodendrocytes of progressive supranuclear palsy, corticobasal degeneration, Pick disease, Parkinson dementia complex of Guam, and certain forms of familial frontotemporal dementia. Apparently, different patterns of hyperphosphorylation, involving the several isoforms of $\tau$ protein, are observed with clinically and pathologically unique manifestations. Most interesting, these other neurodegenerative disorders typically do not have plaques, which are always observed in DAT.\textsuperscript{21}

**Plaques, Tangles, and Dementia**

Although the combination of A$\beta$ plaques and NFTs was soon recognized as a histopathologic hallmark of DAT, the pathogenesis of the development of the clinical syndrome remained unclear for many years. Even Alzheimer acknowledged that these abnormal structures likely were associated with neuronal dysfunction; however, it was uncertain at the time whether the histopathologic findings were cause or effect.\textsuperscript{7,8,11,17} To this day, the relationship between plaques and tangles is also incompletely understood. In Alzheimer’s second patient, no NFTs were noted, leading some investigators to consider that A$\beta$ pathology may precede and even promote $\tau$ pathologies.\textsuperscript{23,48} To date, however, no proved mechanisms directly link the formation of NFTs to A$\beta$ pathology.\textsuperscript{37,49}

Despite lingering uncertainties, most investigators would agree that the A$\beta$ peptide plays a significant role in the pathogenesis of AD. The A$\beta$ peptide is derived from the metabolism of amyloid precursor protein (APP), a transmembrane glycoprotein processed through endoplasmic reticulum and endosomal and lysosomal pathways and possesses extracellular and intracellular components (Fig 2).\textsuperscript{23} The prevalence of at least 10 identified isoforms of APP throughout the body suggests a potential role in normal cellular physiology.\textsuperscript{23,34,43,50} Metabolism of APP can be accomplished through an $\alpha$-secretase pathway or an alternate and competing $\beta$-$\gamma$-secretase pathway. The $\alpha$-secretase pathway entails the cleaving of APP by a protease, known as $\alpha$-secretase, into an extracellular sAPP$\alpha$ fragment and a membrane-spanning C83 fragment but does not produce A$\beta$. The sAPP$\alpha$ fragment may actually possess some neuroprotective function. The alternate $\beta$-$\gamma$-secretase pathway is believed to be problematic in that it generates the A$\beta$ peptide. A protease known as $\beta$-secretase cleaves APP, creating an extracellular sAPP$\beta$ fragment and a membrane-spanning C99 fragment. The C99 fragment is in turn cleaved by yet another protease known as $\gamma$-secretase to form the A$\beta$ peptide, which is ultimately secreted, and the APP intracellular domain (AICD) fragment. The A$\beta$ peptide under certain circum-
stances, can form highly neurotoxic aggregates consisting of oligomers, which subsequently polymerize into larger fibril- lary collections that become plaques.23,37,45 Aβ peptides in the form of oligomers, fibrils, and other species are not only neurotoxic under certain conditions but also proinflammatory and are thought to be involved in oxidative stress. Some inves- tigators have even presented evidence suggesting that Aβ can induce hyperphosphorylation and aggregation of τ protein, but the detailed relationship of amyloid with τ protein and NFTs is not well understood.51

Interest in amyloid metabolism and the potential role of Aβ and APP proteins in DAT was stimulated in part by the discovery of genetic anomalies associated with AD.21 For ex- ample, mutations in presenilin 1 have been associated with a rare early-onset autosomal dominant familial form of DAT. Presenilin 1 is part of the γ-secretase complex and regulates the cleavage of APP by γ-secretase. Mutations tend to increase the ratio of the Aβ-42 form compared with Aβ-40 variety of protein.41,45,50 Aβ-42, which normally constitutes only 5%–10% of all Aβ peptides, tends to aggregate more aggressively than the Aβ-40 when it is present in higher concentrations.23,25

Similarly, mutations in a related protein presenilin 2 also cause a form of autosomal dominant AD.41,45,50 Polymorphism of the gene coding for apolipoprotein E, a protein involved in transport and metabolism of lipids, alters one’s risk for DAT.23,52 The genetic evidence that links Aβ and APP is further bolstered by predisposition of individuals with trisomy 21 to develop dementia in midi-life. These individuals have large numbers of plaques at early ages, thought due to a triple dose of the gene for APP found on chromosome 21 and overexpression of APP.24 Finally, multiple mutations in the APP gene itself cause autosomal dominant familial forms of AD or cerebral amyloid angiopathy. All of these mutations increase total Aβ and Aβ-42 or increase the fibrillogenic properties of Aβ.23

One hypothesis contends that AD begins with a long pre- clinical stage in which Aβ deposition plays a critical role. As plaques gradually accumulate over the years, their neurotoxic effects produce increasing synaptic and neuronal injury as marked by the development of NFTs. When sufficient brain damage exceeds cognitive reserve, the dementia symptoms be- gin to appear.47 Also AD-related proteins may be involved in multiple other neuronal functions that are just now being un- derstood, and future discoveries regarding the pathophysi- ology of AD may shed light on the relationships of amyloid metabolism, plaques, NFTs, and dementia.54

Plaques, Tangles, and Imaging

As mechanisms for the development of AD become better un- derstood, clinical emphasis will increasingly focus on early di- agnosis and evaluation of proposed treatments. Attention has recently concentrated on the condition of mild cognitive im- pairment and its relationship to overt dementia. Limitations of standard psychometric tools have prompted some investiga- tors to consider imaging as a proxy for determining clinical outcomes. Indeed, the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering in partnership with several pharmaceutical firms and national foundations have formed the Alzheimer Disease Neuroimaging Initiative to explore new imaging techniques and optimize methods for image acquisition in longitudinal studies.52 In vivo imaging of cerebral amyloid by using molecular probes and PET, volumetric analysis of select portions of the brain with high-resolution MR imaging, and diffusion tensor image- ing are just a few of the exciting applications of neuroimaging that will develop in the years to come.56–58

Conclusions

Aβ plaques and NFTs are the histopathologic hallmarks of AD. Plaques are predominately composed of Aβ peptide with frequently associated dystrophic neurites and inflammation. NFTs are intracellular inclusions comprising hyperphospho- rylated τ protein that disrupts normal microtubular function. Although the precise pathogenesis of AD is unknown, the bur- den of these 2 inclusions tends to increase with advancing dementia. Alzheimer’s original contribution to the neuro- sciences resides in his recognition of these 2 structures as pathologic manifestations of a neurodegenerative disorder, rather than the normal and expected culmination of aging.

References

1. Möller HJ, Graeber MB. The case described by Alois Alzheimer in 1911: his- torical and conceptual perspectives based on the clinical record and neurohis- tological sections. Eur Arch Psychiatry Clin Neurosci 1998;248:111–22
2. Kircher T, Wormstall H. Alois Alzheimer (1864-1915): student days and first scientific activities. J Geriatr Psychiatry Neurol 1997;10:127–29
3. Brannon WL, Alois Alzheimer (1864–1915). L. Contributions to neurology and psychiatry. J S C Med Assoc 1994;90:399–401
4. Beach TG. The history of Alzheimer’s disease: three debates. J Hist Med Allied Sci 1987;42:327–49
5. Small DH, Cappai R. Alois Alzheimer and Alzheimer’s disease: a centennial perspective. J Neuromed 2006;99:708–10
6. Kreutzberg GW, Gudden W. Alzheimer’s. Trends Neurol 1988;11:256–57
7. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allg Zeitschr Psychiatrie 1907;64:146–48
8. About a peculiar disease of the cerebral cortex: by Alois Alzheimer, 1907 (translated by L. Jarvik and H. Greenson) [in English and German]. Alzheimer Dis Assoc Disord 1987;1:3–8
9. Perusini G. Über klinisch und histologisch eigenartige psychische Erkrankun- gen des späteren Lebensalters. In: Nissl F, Alzheimer A, eds. Histologische und Histopathologische Arbeiten über die Grosshirnrinde: Mit Besonderer Berücksich- tigung der Pathologischen Anatomie der Geisteskrankheiten, Band III, H2. Jena, Germany: Gustav Fischer Verlag; 1910:297–352
10. Lucci B. The contribution of Gaetano Perusini to the definition of Alzheimer’s disease. Ital J Neurol Sci 1999;19:49–52
11. Alzheimer A. Über Eigenartige Krankheitsfälle des Spatener Alters. Gesamte Neuro Psychiatrie 1911;1:356–85
12. Kühnemann HH, Fronhöfer W, Wurster H, et al. Alzheimer’s second patient: Johann F. and his family. Ann Neurol 2002;52:520–23
13. Krea-pelin E. Klinische Psychiatrie, part I. In: Krea-pelin E. Psychiatrische Ein Lehrbuch für Studierende und Arzte, Vol. 2. 8 ed. Leipzig, Germany: Barth 1910;627–28
14. Tollida D. Who was Alzheimer? Nurs Times 1994;90:49
15. Graeber MB, Kosel S, Gradson-Froul E, et al. Histopathology and APOE geno- type of the first Alzheimer disease patient, Auguste D. Neurogenetics 1998;1:223–28
16. Scherer CE. Historical essay: Kraepelin’s description of Alzheimer’s disease. Int J Aging Hum Dev 1985;21:235–38
17. Tonkonogy J, Moak GS. Alois Alzheimer on presenile dementia. J Geriatr Psychiatry Neurol 1988;1:199–206
18. Mott RT, Hulitter CM. Neuropathology of Alzheimer’s disease. Neuroimaging Clin N Am 2005;15:655–65, ix
19. Vannoy JF, Greene JA. Alzheimer’s disease: a brief history. J Tenn Med Assoc 1989;82:15–17
20. Fischer O. Milliare Nekrosen mit drusigen Wucherungen der Neurofibrillen, eine regelmässige Veränderung der Hirnrinde bei seniler Demenz. Monatschr Psychiatr Neurol 1907;22:361–72
21. Goedert M, Spillantini MG. A century of Alzheimer’s disease. J Neuropathol Exp Neurol 2005;64:777–81
22. Blosq P, Marinesco G. Sur les lesions et la pathogenie de l’epilepsie dite essen- tialie. Semaine Med 1892;12:445–48
23. Embimo BP, Lombard J, Pomara N. Pathophysiology of Alzheimer’s disease. Neuroimaging Clin N Am 2005;15:727–53, ix
24. Ellison D, Love S. Dementias. In: Ellison D, Love S, Chimelli L, et al, eds. AJNR Am J Neuroradiol 29:18–22 JAN 2008 www.ajnr.org 21
22 Wippold | AJNR 29 | Jan 2008 | www.ajnr.org

Neuropathology: A Reference Text of CNS Pathology. Edinburgh, UK: Mosby, 2004:551–84

25. Gandy S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Invest 2005;115:1211–29

26. Schechter R, Yen SH, Terry RD. Fibrous astrocytes in senile dementia of the Alzheimer type. J Neuropathol Exp Neurol 1981;40:95–101

27. Wippold FJ 2nd, Perry A, Lennerz J. Neuropathology for the neuroradiologist: Rosenthal fibers. AJNR Am J Neuroradiol 2006;27:958–61

28. Gomes FCA, Paulin D, Moura Neto V. Glial fibrillary acidic protein (GFAP): modulation by growth factors and its implication in astrocyte differentiation. Braz J Med Biol Res 1999;32:619–31

29. Rutka JT, Murakami M, Dirks PB, et al. Role of glial filaments in cells and tumors of glial origin: a review. J Neurosurg 1997;87:420–30

30. Eng LF, Ghimikar RS, Lee Y. Gliial fibrillary acidic protein: GFAP-thirty-one years (1969–2000). Neurochem Res 2000;25:139–51

31. Lowe J, Blanchard A, Morrell K, et al. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson’s disease, Pick’s disease, and Alzheimer’s disease, as well as Rosenthal fibers in cerebellar astrocytomas, cytoplasmic bodies in muscle, and Mallory bodies in alcoholic liver disease. J Pathol 1988;155:9–15

32. Tomokane N, Iwaki T, Tateishi J, et al. Rosenthal fibers share epitopes with alpha B-crystallin, glial fibrillary acidic protein, and ubiquitin, but not vimentin: immunoelectron microscopy with colloidal gold. Am J Pathol 1991;138:875–85

33. Murayama S, Bouldin TW, Suzuki K. Immunocytochemical and ultrastructural studies of eosinophilic granular bodies in astrocytic tumors. Acta Neuropathol (Berl) 1992;83:408–14

34. Hardy J, Allsop D. Amyloid deposition as the central event in the etiology of Alzheimer’s disease. Trends Pharmacol Sci 1991;12:383–88

35. Kidd M. Alzheimer’s disease: an electron microscopical study. Brain 1966;87:307–20

36. Yamaguchi H, Hirai S, Morimatsu M, et al. Diffuse type of senile plaques in the brains of Alzheimer-type dementia. Acta Neuropathol (Berl) 1988;77:113–19

37. Armstrong RA. Plaques and tangles and the pathogenesis of Alzheimer’s disease. Folia Neuropathol 2006;44:1–11

38. Pearce JM. Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2000;68:348

39. Sheng IG, Zhou YQ, Mrak RE, et al. Progressive neuronal injury associated with amyloid plaque formation in Alzheimer disease. J Neuropathol Exp Neurol 1998;57:714–17

40. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239–59

41. Pastorino L, Lu KP. Pathogenic mechanisms in Alzheimer’s disease. Eur J Pharmacol 2006;545:29–38

42. Delacourte A. Tauopathies: recent insights into old diseases. Folia Neuropathol 2005;43:244–57

43. Goedert M, Kug A, Crowther RA. Tau protein, the paired helical filament and Alzheimer’s disease. J Alzheimers Dis 2006;9:195–207

44. Goedert M, Spillantini MG, Davies SW. Filamentous nerve cell inclusions in neurodegenerative diseases. Curr Opin Neurobiol 1998;8:619–32

45. Drachman DA. Aging of the brain, entropy, and Alzheimer disease. Neurology 2006;67:1340–52

46. Price JL, Davis PB, Morris JC, et al. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer’s disease. Neurobiol Aging 1991;12:295–312

47. Price JL, Morris JC. Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol 1999;45:358–68

48. Turner RS. Alzheimer’s disease. Semin Neurol 2006;26:499–506

49. Terry RD, Gonatas NK, Weiss MA. Ultrastructural studies in Alzheimer’s presenile dementia. Am J Pathol 1996;144:269–97

50. Bayer TA, Wirths O, Maiteny K, et al. Key factors in Alzheimer’s disease: beta-amyloid precursor protein processing, metabolism and intraneuronal transport. Brain Pathol 2001;11:1–11

51. Sivaprasakam K. Towards a unifying hypothesis of Alzheimer’s disease: cholinergic system linked to plaques, tangles and neuroinflammation. Curr Med Chem 2006;13:2179–88

52. Holtzman DM. Role of apoE/Abeta interactions in the pathogenesis of Alzheimer’s disease and cerebral amyloid angiopathy. J Mol Neurosci 2001;17:147–55

53. Golde TE, Eckman CB, Younkin SG. Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer’s disease. Biochim Biophys Acta 2000;1502:172–87

54. Forero DA, Casadesus G, Perry G, et al. Synaptic dysfunction and oxidative stress in Alzheimer’s disease: emerging mechanisms. J Cell Mol Med 2006;10:796–805

55. Mueller SG, Weiner MW, Thal LJ, et al. The Alzheimer’s disease neuroimaging initiative. Neuroimaging Clin N Am 2005;15:869–77, xi–ii

56. Coleman RE. Positron emission tomography diagnosis of Alzheimer’s disease. Neuroimaging Clin N Am 2005;15:837–46, x

57. Krishnan S, Talley BD, Slavin MJ, et al. Current status of functional MR imaging, perfusion-weighted imaging, and diffusion-tensor imaging in Alzheimer’s disease diagnosis and research. Neuroimaging Clin N Am 2005;15:453–68, xi

58. Lascola C. Molecular imaging in Alzheimer’s disease. Neuroimaging Clin N Am 2005;15:827–35, x–xi